Loretta J. Nastoupil, MD, is an Associate Professor, Director of the Lymphoma Outcomes Database and Section Chief of New Drug Development in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, Houston, TX.
Dr Nastoupil received her medical degree in 2007 from the University of Texas Southwestern Medical Center in Dallas, TX, after which she completed her clinical residency in medicine at the Washington University School of Medicine in St Louis, MO, followed by a residency in hematology and medical oncology at the Emory University School of Medicine in Atlanta, GA.
Speaking on disparities in survival and outcomes for patients with DLBCL
Dr Nastoupil’s primary research focuses on examining the disparities in lymphoma survival as a way to try and curate more effective clinical trials for high-risk patients. In particular, Dr Nastoupil has investigated methods of addressing disparities which affect the use of chemoimmunotherapy among patients with diffuse large B-cell lymphoma (DLBCL). This has included translational work, molecularly profiling tumors from patients with DLBCL to identify biomarkers which may explain racial differences in the presentation and survival outcomes in DLBCL.
As the Director of the Lymphoma Outcomes Database, Dr Nastoupil also researches predictors and possible triggers for lymphomagenesis.